semaglutide / tirzepatide versus Once Weekly in Patients with Type 2 Diabetes Semaglutide vs Tirzepatide vs Liraglutide

According to the SUSTAIN trials, semaglutide has shown significant weight loss in participants

Gastrointestinal Discomfort: In some cases, individuals using BPC-157 may experience mild gastrointestinal discomfort, such as bloating, nausea, or abdominal pain

In that case, skip the missed dose and resume your normal schedule on your next injection day

reductions in waist circumference were associated with lower MACE risk and accounted for approximately one-third of the treatment effect, although this likely reflects a risk marker rather than a proven causal mediator

Here is what that looks like: Each step reduces your volume by 0.25 ml (at 10 mg/ml) or 0.125 ml (at 20 mg/ml)

A prescriber focused solely on weight loss may not flag a dropping TSH as significant, while an endocrinologist managing Hashimoto's may not anticipate thyroid dose needs changing during weight loss treatment they're not directly supervising